Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Transforaminal Epidural Injection in Acute Sciatica

Not Applicable

Recruiting

Conditions: Sciatica
Sciatica Due to Intervertebral Disc Disorder
Sciatic Radiculopathy

Interventions: Drug: Lidocaine
Drug: Methylprednisolone Acetate
Drug: Dexamethasone

First Posted Date: 2019-04-23

Last Posted Date: 2023-10-19

Lead Sponsor: C.L.A.Vleggeert-Lankamp

Target Recruit Count: 142

Registration Number: NCT03924791

Locations: 🇳🇱
Spaarne Gasthuis, Hoofddorp, Netherlands

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

Phase 3

Active, not recruiting

Conditions: B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma
Down Syndrome

Interventions: Drug: Asparaginase Erwinia chrysanthemi
Drug: Cyclophosphamide
Biological: Blinatumomab
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Mercaptopurine Oral Suspension
Drug: Methotrexate
Drug: Pegaspargase
Radiation: Radiation Therapy
Drug: Prednisone
Drug: Prednisolone
Drug: Thioguanine
Drug: Vincristine Sulfate

First Posted Date: 2019-04-16

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6720

Registration Number: NCT03914625

Locations: 🇨🇦
IWK Health Centre, Halifax, Nova Scotia, Canada
🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

and more 225 locations

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Granulocyte Colony-Stimulating Factor

First Posted Date: 2019-04-10

Last Posted Date: 2024-07-19

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 18

Registration Number: NCT03909412

Locations: 🇺🇸
Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States

Effect of Intravenous Dexamethasone With Pudendal Nerve Block on Postoperative Pain in Pediatric Hypospadias Repair

Phase 4

Completed

Conditions: Hypospadias
Postoperative Pain

Interventions: Drug: Dexamethasone

First Posted Date: 2019-04-04

Last Posted Date: 2019-04-04

Lead Sponsor: Dr Sonia ben khalifa (PhD)

Target Recruit Count: 70

Registration Number: NCT03902249

Ideal Steroids for Asthma Treatment in the PICU

Phase 4

Completed

Conditions: Asthma Childhood

Interventions: Drug: Dexamethasone

First Posted Date: 2019-04-03

Last Posted Date: 2024-02-23

Lead Sponsor: Johns Hopkins All Children's Hospital

Target Recruit Count: 92

Registration Number: NCT03900624

Locations: 🇺🇸
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States

Effects of Combined Topical and Systemic Steroid Administrations on Better Early Postoperative Pain Management in Total Knee Arthroplasty

Phase 4

Conditions: Total Knee Replacement

Interventions: Drug: Placebos
Drug: Triamcinolone
Drug: Dexamethasone

First Posted Date: 2019-04-03

Last Posted Date: 2019-04-03

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 180

Registration Number: NCT03901768

Locations: 🇭🇰
Department of Orthopaedics and Traumatology, The University of Hong Kong, Hong Kong, Hong Kong

Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures

Phase 4

Recruiting

Conditions: Distal Radius Fracture

Interventions: Drug: Dexamethasone
Drug: Methylprednisolone

First Posted Date: 2019-04-01

Last Posted Date: 2024-05-01

Lead Sponsor: C. Liam Dwyer

Target Recruit Count: 200

Registration Number: NCT03898154

Locations: 🇺🇸
Geisinger Woodbine, Danville, Pennsylvania, United States

Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

Phase 2

Active, not recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2019-03-27

Last Posted Date: 2022-09-15

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 16

Registration Number: NCT03891355

Locations: 🇮🇹
AOU Senese - U.O.C. Ematologia, Siena, Italy
🇮🇹
A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria, Torino, Italy
🇮🇹
Azienda sanitaria-universitaria integrata Trieste (ASUITS) - SC Ematologia, Trieste, Italy

and more 8 locations